• Korean Journal of Radiology
• /
• 제23권7호
• /
• pp.773-774
• /
• 2022

• Clinical and Experimental Vaccine Research
• /
• 제12권3호
• /
• pp.249-259
• /
• 2023

Purpose: Since patients on hemodialysis (HD) are known to be vulnerable to coronavirus disease 2019 (COVID-19), many studies were conducted regarding the effectiveness of the COVID-19 vaccine in HD patients in Western countries. Here, we assessed antibody response of HD patients for 6 months post-vaccination to identify the duration and effectiveness of the COVID-19 vaccine in the Asian population. Materials and Methods: We compared antibody response of the COVID-19 vaccine in HD patients with healthy volunteers. Patient and control groups had two doses of ChAdOx1 nCoV-19 and mRNA-1273, respectively. Immunoglobulin G (IgG) was measured before vaccination, 2 weeks after the first dose, 2 and 4 weeks, 3 and 6 months after the second dose. Neutralizing antibody was measured before vaccination and at 2 weeks, 3 and 6 months after second dose. Since the third dose was started in the middle of the study, we analyzed the effect of the third dose as well. Results: Although antibody production was weaker than the control group (n=22), the patient group (n=39) showed an increase in IgG and neutralizing antibody after two doses. And, 21/39 patients and 14/22 participants had a third dose (BNT162b2 or mRNA-1273 in the patient group, mRNA-1273 in the control group), and it did not affect antibody response in both group. Trend analysis showed IgG and neutralizing antibody did not decrease over time. Age, sex, and HD vintage did not affect antibody production in HD patients. Patients with higher body mass index displayed better seroresponse, while those on immunosuppressants showed poor seroresponse. Conclusion: Two doses of vaccination led to significant antibody response in HD patients, and the antibody did not wane until 6 months.

• Childhood Kidney Diseases
• /
• 제26권2호
• /
• pp.91-96
• /
• 2022

The messenger RNA-based vaccine for the coronavirus disease 2019 (COVID-19) may induce glomerulonephritis, including immunoglobulin A nephropathy (IgAN). New-onset IgAN triggered by vaccination against COVID-19 has been reported rarely, especially in children. Herein, we report a pediatric case of newly diagnosed IgAN after administration of the Pfizer vaccine for COVID-19. A 12-year-old girl was referred to our hospital for evaluation of gross hematuria after inoculation with the second dose of Pfizer's COVID-19 vaccine; she had no adverse effects after the first dose. At the time of admission, she showed heavy proteinuria and persistent hematuria. Kidney biopsy revealed an IgAN, and she was treated with an oral steroid and an angiotensin-converting enzyme inhibitor. Four months after discharge, the proteinuria and hematuria resolved completely.

• Clinical Nutrition Research
• /
• 제12권4호
• /
• pp.269-282
• /
• 2023

Vitamin D participates in the biological function of the innate and adaptive immune system and inflammation. We aim to specify the effectiveness of the vitamin D supplementation on the side effects BioNTech, Pfizer vaccination, and immunoglobulin G response against severe acute respiratory syndrome coronavirus 2 in subjects tested positive for coronavirus disease 2019 (COVID-19). In this multi-center randomized clinical trial, 498 people tested positive for COVID-19 were divided into 2 groups, receiving vitamin D capsules or a placebo (1 capsule daily, each containing 600 IU of vitamin D) over 14-16 weeks. Anthropometric indices and biochemical parameters were measured before and after the second dose of vaccination. Fourteen to 16 weeks after supplementation, the intervention group had an immunoglobulin G (IgG) increase of 10.89 ± 1.2 g/L, while the control group had 8.89 ± 1.3 g/L, and the difference was significant between both groups (p = 0.001). After the second dose of vaccination, the supplement group significantly increased their 25-hydroxy vitamin D from initially 28.73 ± 15.6 ng/mL and increased to 46.48 ± 27.2 ng/mL, and the difference between them was significant. Those with a higher body mass index (BMI) had the most of symptoms, and the difference of side effects according to BMI level was significantly different. In 8 weeks after supplementation obese participants had the lowest IgG levels than overweight or normal subjects. The proportion of all types of side effects on the second dose was significantly diminished compared with the first dose in the intervention group. Supplementation of 600 IU of vitamin D3 can reduce post-vaccination side effects and increase IgG levels in participants who received BioNTech, Pfizer vaccine.

• 대한한의학회지
• /
• 제44권3호
• /
• pp.47-58
• /
• 2023

Objectives: This study aimed to investigate the epidemiological characteristics of COVID-19 in Chungju City from July to December 2021. Methods: The authors processed and analyzed the epidemiological analysis report written by researcher. The estimated reproduction rate was analyzed using web-based software that calculates time-varying reproduction numbers. The results were analyzed through univariate multiple regression analysis, with a maximum significance level set at 0.05. Results: During the study period, a total of 1,188 patients were identified, with 7.9% of them progressing to a severe status. The maximum reproduction rate recorded was 3.48. Factors associated with the transition to a severe status included the presence of symptoms at the time of diagnosis, lack of vaccination, and belonging to the age group over 40. Conclusion: Based on the findings of this study, it can be strongly supported that the measures implemented in Chungju City, such as social distancing, vaccination, and preemptive diagnostic tests, were appropriate. Furthermore, it demonstrates that Chungju City effectively managed the impact of COVID-19. Korean Medicine Doctors made significant contributions to the epidemiological investigations of COVID-19. To comprehensively manage infectious diseases, it is crucial to provide administrative and legal support and encourage active research to expand the role of Korean Medicine Doctors in this area.

• IMMUNE NETWORK
• /
• 제22권3호
• /
• pp.23.1-23.12
• /
• 2022

Natural infection with severe acute respiratory syndrome-coronavirus-2 or vaccination induces virus-specific immunity protecting hosts from infection and severe disease. While the infection-preventing immunity gradually declines, the severity-reducing immunity is relatively well preserved. Here, based on the different longevity of these distinct immunities, we develop a mathematical model to estimate courses of endemic transition of coronavirus disease 2019 (COVID-19). Our analysis demonstrates that high viral transmission unexpectedly reduces the rates of progression to severe COVID-19 during the course of endemic transition despite increased numbers of infection cases. Our study also shows that high viral transmission amongst populations with high vaccination coverages paradoxically accelerates the endemic transition of COVID-19 with reduced numbers of severe cases. These results provide critical insights for driving public health policies in the era of 'living with COVID-19.'

• 대한한방내과학회지
• /
• 제44권5호
• /
• pp.957-967
• /
• 2023

Background: According to Vaccine Adverse Events Reporting System data, generalized edema followed by the COVID-19 vaccine is uncommon, with only 333 reported cases, and of those, 224 (69%) are associated with the Pfizer-BioNTech vaccine. Case report: A 76-year-old male patient with heart failure with preserved ejection fraction presented with spontaneous generalized edema and otherwise normal cardiac exams following administration of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination that had lasted for approximately 60 days and was treated successfully using Korean medicine treatment. After the administration of Korean medicine treatment, the patient's symptoms in the bilateral limbs were dramatically controlled, without recurrence, for 2 months. As a result, generalized edema, which had been present for approximately 50 days, dramatically improved. Conclusion: This clinical case study suggests that a Korean medicine approach with Mokbangki-tang and Oryeong-san might be effective for the pleural effusion resolution of generalized edema after COVID-19 vaccination.

• 핵의학기술
• /
• 제26권2호
• /
• pp.32-36
• /
• 2022

코로나바이러스의 대유행으로 인하여 백신접종이 시작되었고 코로나 백신으로 인한 림프절병증의 여러사례가 발표되고 있으며, ¹⁸F-FDG PET/CT에서는 액와 림프절에 위양성 섭취를 유발한다는 보고가 있다. 이에 코로나 백신 접종 후 기간에 따른 접종 측 액와 림프절의 SUVmax의 변화 양상을 평가하고자 한다. 환자는 접종 후 기간을 0~2주, 3~6주, 7~10주, 11주 이상으로 4개 집단으로 나누었고 FDG를 3.7 MBq/kg을 주입하고 한 시간 뒤 1 bed 당 2분 동안 촬영했다. 장비는 Discovery 600 (GE Healthcare, MI, USA)을 사용하였다. 검사 후 핵의학 판독의가 육안평가를 진행하였고, 그 결과를 토대로 접종 측액와 림프절의 섭취 여부를 구분하였다. 그 후에 유방암 부위 반대 측 팔에 백신이 접종되었으며 그로 인해 섭취가 발생한 액와 림프절에 관심 영역을 그려 SUVmax를 측정하였다. 백신접종 후 기간이 지남에 따라 접종 측 액와 림프절에 섭취된 환자의 비율과 SUVmax는 감소하였다. 또한 4개 집단의 섭취된 액와 림프절의 SUVmax를 Kruskal-Wallis test를 한 결과 4개 집단 간 SUVmax에서 통계적으로 유의한 차이가 있었고(P<0.05) Mann-Whitney test로 사후 검정한 결과 0~2주는 다른 집단과 모두 유의한 차이가 있었으나(P<0.05) 나머지 3개 집단 간에는 유의한 차이가 없는 것을 알 수 있었다. 이러한 경향성은 참고자료로써 유용할 것으로 사료되며 PET/CT 검사 전 코로나 백신접종 정보를 기록하여 진행하는 것을 권고한다.

• 보건행정학회지
• /
• 제31권1호
• /
• pp.1-4
• /
• 2021

With this as a momentum of approval Pfizer vaccine against coronavirus disease 2019 (COVID-2019), it is changed to the era of vaccine rapidly. Most countries are trying to reserve effective vaccines and inoculate vaccines into high-risk populations for achieving community immunity. I reviewed several vaccine-related issues to be confronted for moving up to the end of COVID-2019: the efficacy and effectiveness of the approved vaccines, the priorities for vaccination into target groups, side effects, and distrust towards COVID-2019 vaccines. Evidence-based decision-making in the policy process and collaboration with professional groups are the most effective strategies for driving successful vaccination policy.

• Pediatric Infection and Vaccine
• /
• 제29권1호
• /
• pp.16-27
• /
• 2022

우리 나라는 2022년 3월에 5-11세 소아의 코로나19 예방접종을 시작하였다. 5-11세 소아에서 중증 코로나19가 발생할 위험은 높지 않기 때문에, 이 연령에 대한 코로나19 예방접종 정책은 각 국가의 상황에 따라 상이하다. 본 논문에서는 해외 주요 국가의 5-11세 소아 코로나19 예방접종 관련 정책을 살펴보고, 5-11세 코로나19 예방접종을 시작하는 우리 나라에서 고려할 사항에 대하여 언급하였다.